1 / 5

MDP301

MDP301. Mini Oral Presentation Disseminating the MDP301 Results A Critical Approach to the Dissemination of Trial Results in a Connected World Roger Tatoud , Ph.D.

makara
Download Presentation

MDP301

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MDP301 • Mini Oral Presentation • Disseminating the MDP301 Results • A Critical Approach to the Dissemination of Trial Results in a Connected World • Roger Tatoud, Ph.D. An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5 gels for the prevention of vaginally acquired HIV infection Funded by UK MRC and DFID

  2. MDP 301 • Phase 3 trial conducted in 16 centres across South-Eastern Africa between 2005 and 2009. • 16,000 women screened and 9,400 enrolled in an efficacy study investigating the candidate microbicide PRO2000 for the prevention of vaginal HIV acquisition . • PRO2000 had previously been been trialled by the MTN in the Phase 2 HPTN035 and showed promising result in February 2009 (30% reduction in risk, not statistically significant) • This result was not confirmed by the MDP 301 in December 2009 which demonstrated that the PRO 2000 gel was ineffective. • The MDP dissemination work started as early as August 2008. In March 2009 expectations where high and work was already well advanced on the dissemination of a number of scenarios. • How to disseminate results across many different countries and stakeholders? • How to manage a failed hope from HPTN 035 to MDP301?

  3. Planning DisseminationFrom paper to realities “This is simply sanctioned murder (Grievous Bodily Harm) FROM THE WEST, in the name of scientific research, by the Medical Research Council and DFID at a cost of £40 million to infect ONLY one hundred and twenty-three (123) simple, cheap, black, AFRICAN women's lives in Uganda, Tanzania, South Africa and Zambia. The lead researcher says, "IT IS DISHEARTENING!" No it is MURDER!” Dr. Edwin Mapara, London. Diaspora voices, Yahoo Group.

  4. UK MDP ADV. Africa Zambia USA Mazabuka HIV Prevention ADV. Ppts Partners + +

  5. Dissemination of Clinical Trial Results in a Connected World The Internet • Research does not happen in a vacuum • Political context (we do research, not politics, but should we?) • Cultural and social context (North/South tension, Women in society, Science & Society) • What do we communicate • How? To whom? When? • Identify & acknowledge Networks and their overlaps (or lack thereof) • Limitations of what can be done • Long term planning • Systemic and systematic approach to dissemination Your Best Friends and Worst Enemies

More Related